239 Days: Oncopeptides' Myeloma Drug Pepaxto Comes Off Market Just Months After Accelerated Approval

 
• By Sue Sutter
  
Sinking ship
An adverse survival trend in a confirmatory trial sank Pepaxto's chances of remaining on the market • Source: Alamy
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from Drug Safety

More from Pink Sheet